Cite
Oskarsson B, Maragakis N, Bedlack RS, et al. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegener Dis Manag. 2021;11(6):431-443doi: 10.2217/nmt-2021-0042.
Oskarsson, B., Maragakis, N., Bedlack, R. S., Goyal, N., Meyer, J. A., Genge, A., Bodkin, C., Maiser, S., Staff, N., Zinman, L., Olney, N., Turnbull, J., Brooks, B. R., Klonowski, E., Makhay, M., Yasui, S., & Matsuda, K. (2021). MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegenerative disease management, 11(6), 431-443. https://doi.org/10.2217/nmt-2021-0042
Oskarsson, Björn, et al. "MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design." Neurodegenerative disease management vol. 11,6 (2021): 431-443. doi: https://doi.org/10.2217/nmt-2021-0042
Oskarsson B, Maragakis N, Bedlack RS, Goyal N, Meyer JA, Genge A, Bodkin C, Maiser S, Staff N, Zinman L, Olney N, Turnbull J, Brooks BR, Klonowski E, Makhay M, Yasui S, Matsuda K. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegener Dis Manag. 2021 Dec;11(6):431-443. doi: 10.2217/nmt-2021-0042. Epub 2021 Nov 24. PMID: 34816762.
Copy
Download .nbib